Biofrontera Reports Q3 2026 Revenue Growth Amidst Liquidity Concerns and NASDAQ Compliance Issues
Biofrontera (BFRI) reported third-quarter 2026 net product revenue of $9.1 million, a 29.8% increase year-over-year driven by higher Ameluz unit volumes and lamp sales. Despite the top-line growth and improved gross margins, the company faces significant financial headwinds, including a net loss of $6.4 million ($0.42 per share) and a decrease in cash reserves to $3.2 million. The company's financial position has triggered critical warnings; management expressed substantial doubt regarding Biofrontera's ability to continue as a going concern for the next 12 months due to liquidity constraints. Additionally, a stockholders' deficit of $200,000 means the company currently fails to meet NASDAQ minimum stockholders' equity requirements.